Cargando…

Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer

The C-terminal binding protein (CtBP) is a NADH-dependent transcriptional repressor that links carbohydrate metabolism to epigenetic regulation by recruiting diverse histone modifying complexes to chromatin. Here, global profiling of CtBP in breast cancer cells reveals that it drives epithelial to m...

Descripción completa

Detalles Bibliográficos
Autores principales: Di, Li-Jun, Byun, Jung S., Wong, Madeline M., Wakano, Clay, Taylor, Tara, Bilke, Sven, Baek, Songjoon, Hunter, Kent, Yang, Howard, Lee, Maxwell, Zvosec, Celia, Khramtsova, Galina, Cheng, Fan, Perou, Charles M., Miller, C. Ryan, Raab, Rachel, Olopade, Olufunmilayo I., Gardner, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3768144/
https://www.ncbi.nlm.nih.gov/pubmed/23385593
http://dx.doi.org/10.1038/ncomms2438
Descripción
Sumario:The C-terminal binding protein (CtBP) is a NADH-dependent transcriptional repressor that links carbohydrate metabolism to epigenetic regulation by recruiting diverse histone modifying complexes to chromatin. Here, global profiling of CtBP in breast cancer cells reveals that it drives epithelial to mesenchymal transition, stem cell pathways, and genome instability. CtBP expression induces mesenchymal and stem cell-like features while CtBP depletion or caloric restriction reverses gene repression and increases DNA repair. Multiple members of the CtBP-targeted gene network are selectively down-regulated in aggressive breast cancer subtypes. Differential expression of CtBP-targeted genes predicts poor clinical outcome in breast cancer patients, and elevated levels of CtBP in patient tumors predict shorter median survival. Finally, both CtBP promoter targeting and gene repression can be reversed by small molecule inhibition. These findings define broad roles for CtBP in breast cancer biology and suggest novel chromatin-based strategies for pharmacologic and metabolic intervention in cancer.